Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of “Buy” from Analysts
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $35.09.
Several equities research analysts recently weighed in on SNDX shares. The Goldman Sachs Group started coverage on Syndax Pharmaceuticals in a report on Wednesday, October 11th. They set a “buy” rating and a $30.00 price target for the company. JPMorgan Chase & Co. increased their price target on Syndax Pharmaceuticals from $36.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, October 17th. HC Wainwright increased their price target on Syndax Pharmaceuticals from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 2nd. StockNews.com assumed coverage on Syndax Pharmaceuticals in a report on Thursday, October 5th. They set a “sell” rating for the company. Finally, Bank of America assumed coverage on Syndax Pharmaceuticals in a report on Wednesday, October 25th. They issued a “buy” rating and a $29.00 target price for the company.
Get Our Latest Stock Analysis on SNDX
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its position in shares of Syndax Pharmaceuticals by 2.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 20,551 shares of the company’s stock valued at $523,000 after buying an additional 517 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Syndax Pharmaceuticals by 5.6% in the second quarter. Commonwealth Equity Services LLC now owns 11,495 shares of the company’s stock valued at $241,000 after buying an additional 605 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Syndax Pharmaceuticals by 12.6% in the second quarter. Ameritas Investment Partners Inc. now owns 5,441 shares of the company’s stock valued at $114,000 after buying an additional 609 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Syndax Pharmaceuticals by 1.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,492 shares of the company’s stock valued at $821,000 after buying an additional 615 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Syndax Pharmaceuticals by 0.9% in the second quarter. California State Teachers Retirement System now owns 70,134 shares of the company’s stock valued at $1,468,000 after buying an additional 648 shares in the last quarter.
Syndax Pharmaceuticals Trading Down 5.3 %
SNDX stock opened at $19.67 on Tuesday. The company has a market capitalization of $1.37 billion, a P/E ratio of -7.62 and a beta of 1.07. Syndax Pharmaceuticals has a twelve month low of $11.22 and a twelve month high of $29.86. The business has a 50 day simple moving average of $14.80 and a 200-day simple moving average of $17.56.
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07. Research analysts predict that Syndax Pharmaceuticals will post -2.97 EPS for the current fiscal year.
Syndax Pharmaceuticals Company Profile (Get Free Report
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).
Further Reading
NASDAQ: SNDX” width=”600″ height=”385″ loading=”lazy”>
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Syndax Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Syndax Pharmaceuticals wasn’t on the list.
While Syndax Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.